CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, September 13th.
According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “
CSPC Pharmaceutical Group (CHPTY) remained flat at $80.04 during midday trading on Wednesday. CSPC Pharmaceutical Group has a 12 month low of $48.25 and a 12 month high of $80.04. The firm has a 50 day moving average price of $74.62 and a 200 day moving average price of $69.72. The firm has a market cap of $9.69 billion and a PE ratio of 32.02.
WARNING: This piece of content was originally published by BBNS and is the property of of BBNS. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://baseballnewssource.com/markets/cspc-pharmaceutical-group-ltd-chpty-upgraded-at-zacks-investment-research/1643753.html.
CSPC Pharmaceutical Group Company Profile
CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with our FREE daily email newsletter.